Comparative Pharmacology
Head-to-head clinical analysis: STALEVO 125 versus STALEVO 200.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STALEVO 125 versus STALEVO 200.
STALEVO 125 vs STALEVO 200
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stalevo 125 is a combination of carbidopa, levodopa, and entacapone. Levodopa is a precursor to dopamine that crosses the blood-brain barrier and is converted to dopamine, replenishing striatal dopamine levels. Carbidopa inhibits peripheral decarboxylation of levodopa, increasing its availability to the brain. Entacapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT), primarily in the periphery, which reduces the metabolism of levodopa to 3-O-methyldopa, prolonging the half-life of levodopa.
STALEVO 200 contains carbidopa, levodopa, and entacapone. Carbidopa inhibits peripheral decarboxylation of levodopa, increasing levodopa availability to the brain. Levodopa is decarboxylated to dopamine in the brain, restoring dopaminergic activity in the striatum. Entacapone inhibits catechol-O-methyltransferase (COMT), reducing peripheral metabolism of levodopa and prolonging its half-life.
One tablet of STALEVO 125 (levodopa 100 mg, carbidopa 25 mg, entacapone 200 mg) orally, one tablet per dose, up to maximum 10 tablets per day. Frequency: typically every 4-6 hours while awake, adjusted based on response.
One tablet (levodopa 200 mg, carbidopa 50 mg, entacapone 200 mg) administered orally 3 to 4 times daily, adjusted based on response and tolerability.
None Documented
None Documented
Levodopa: 1-3 hours (short half-life necessitates frequent dosing with carbidopa to reduce peripheral metabolism). Carbidopa: 1-2 hours (not clinically significant alone). Entacapone: 0.4-0.7 hours (short half-life; acts primarily during absorption phase of levodopa).
Levodopa: 1.3 hours (with carbidopa). Entacapone: 0.4-0.7 hours. Carbidopa: 1-2 hours. Terminal half-life of levodopa is extended to ~1.5-2 hours in combination; clinical dosing is every 4-6 hours.
Levodopa: renal excretion of metabolites (dopamine, DOPAC, HVA) accounts for >70% of dose; <1% unchanged. Carbidopa: renal excretion of unchanged drug (~30%) and metabolites (~70%). Entacapone: primarily fecal excretion (~90%) with ~10% renal; entacapone glucuronide and unchanged drug in urine.
Carbidopa: 70% renal (unchanged and metabolites), 30% fecal. Levodopa: 70-80% renal (metabolites), <10% fecal. Entacapone: 90% fecal (unchanged and metabolites), 10% renal.
Category C
Category C
Anti-Parkinson Agent
Anti-Parkinson Agent